- Home
- Technology
-
Products & Services
- COVID-19 Research Support
-
Oligo Synthesis Service
- Custom DNA Oligonucleotides Synthesis
- Custom RNA Oligonucleotides Synthesis
- Custom mRNA Synthesis
- DNA/RNA Modification
- Custom Oligo Synthesis
- Antisense Oligonucleotides Synthesis
- Oligo Modifications
- GMP Oligonucleotide Manufacturing Services
- CpG oligonucleotides (CpG ODN)
- Diagnostic Probes & Oligos
- Custom LNA Synthesis
- DNA/RNA Synthesis Reagents
- Oligo Analysis & Purification
- siRNA Products & Services
- Drug Delivery System
- Professional Support for mRNA Vaccines
-
Support
-
News
- mRNA-1647，the first infectious disease mRNA vaccine to enter the second phase of research
- Onpattro, The First FDA-approved RNAi Drug
- FDA approves first RNAi treatment for inherited rare diseases
- Alnylam's third RNAi therapy Lumasiran was approved by the European Union for the treatment of primary hyperoxaluria type 1 (PH1)
- Competing for the last mile of vaccine research and development, mRNA vaccines become a hot spot for competition
- Resources
- FAQs
-
News
- Events
- Ordering
- About Us
- Contact Us
- Careers
